|
1
|
Zelenetz AD: Biosimilars in oncology.
Oncol Hematol Rev. 12:22–28. 2016.
|
|
2
|
Campen CJ: Integrating biosimilars into
oncology practice: Implications for the advanced practitioner. J
Adv Pract Oncol. 8:688–699. 2017.PubMed/NCBI
|
|
3
|
Robinson J: Ten things pharmacists should
know about biologics and biosimilars. Pharmaceutical J. Oct
8–2018.(Epub ahead of print).
|
|
4
|
Tabernero J, Vyas M, Giuliani R, Arnold D,
Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J,
et al: Biosimilars: A position paper of the European Society for
Medical Oncology, with particular reference to oncology
prescribers. ESMO Open. 1:e0001422017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mellstedt H: Clinical consideration for
biosimilar antibodies. EJC Suppl. 11:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel KB, Arantes LH Jr, Tang WY and Fung
S: The role of biosimilars in value-based oncology care. Cancer
Manag Res. 10:4591–4602. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan JC and Chan AT: Biologics and
biosimilars: What, why and how? ESMO Open. 2:e0001802017.
View Article : Google Scholar
|
|
8
|
Kaida-Yip F, Deshpande K, Saran T and Vyas
D: Biosimilars: Review of current applications, obstacles, and
their future in medicine. World J Clin Cases. 6:161–166. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lyman GH: Emerging opportunities and
challenges of biosimilars in oncology practice. J Oncol Pract. 13
(Suppl 9):7s–9s. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janjigian YY, Bissig M, Curigliano G,
Coppola J and Latymer M: Talking to patients about biosimilars.
Future Oncol. 14:2403–2414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chopra R and Lopes G: Improving access to
cancer treatments: The role of biosimilars. J Glob Oncol.
3:596–610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cook JW, McGrath MK, Dixon MD, Switchenko
JM, Harvey RD and Pentz RD: Academic oncology clinicians'
understanding of biosimilars and information needed before
prescribing. Ther Adv Med Oncol. Jan 6–2019.(Epub ahead of print).
doi: 10.1177/1758835918818335. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zalcberg J: Biosimilars are coming: Ready
or not. Intern Med J. 48:1027–1034. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rugo HS, Rifkin RM, Declerck P, Bair AH
and Morgan G: Demystifying biosimilars: Development, regulation and
clinical use. Future Oncol. 15:777–790. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coiffier B: Preparing for a new generation
of biologic therapies: Understanding the development and potential
of biosimilar cancer therapeutics. Future Oncol. 13:1–3. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karalis VD: From bioequivalence to
biosi.milarity: The rise of a novel regulatory framework. Drug Res
(Stuttg). 66:1–6. 2016.PubMed/NCBI
|
|
17
|
Harston A: How the U.S. Compares to Europe
on Biosimilar Approvals and Products in the Pipeline. Rothwell
Figg; May 1–2019
|
|
18
|
Declerck P, Bakalos G, Zintzaras E, Barton
B and Schreitmüller T: Monoclonal antibody biosimilars in oncology:
Critical appraisal of available data on switching. Clin Ther.
40:798–809.e2. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cazap E, Jacobs I, McBride A, Popovian R
and Sikora K: Global acceptance of biosimilars: Importance of
regulatory consistency, education, and trust. Oncologist.
23:1188–1198. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lucio SD, Stevenson JG and Hoffman JM:
Biosimilars: Implications for health-system pharmacists. Am J
Health Syst Pharm. 70:2004–2017. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alnahar S, Elliott RA and Smith MD:
Biosimilar uptake by British local formularies: A cross sectional
study. Int J Clin Pharm. 39:1055–1060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farhat F, Torres A, Park W, de Lima Lopes
G, Mudad R, Ikpeazu C and Abi Aad S: The concept of Biosimilars:
From characterization to Evolution-A narrative review. Oncologist.
23:346–352. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Azevedo V, Dörner T, Strohal R, Isaacs J,
Castañeda-Hernández G, Gonçalves J and McInnes I: Biosimilars:
Considerations for clinical practice. Considerations Med. 1:13–18.
2017. View Article : Google Scholar
|
|
24
|
Aapro M, Krendyukov A, Schiestl M and
Gascón P: Epoetin Biosimilars in the treatment of
chemotherapy-induced anemia: 10 years' experience gained. BioDrugs.
32:129–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ludwig H, Bokemeyer C, Aapro M, Boccadoro
M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I and MacDonald
K: Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis
with biosimilar filgrastim in solid tumors versus hematological
malignancies: MONITOR-GCSF study. Future Oncol. 15:897–907. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aapro M: Biosimilars in oncology: Current
and future perspectives. Gen Biosimilars Initiative J (GaBI
Journal). 2:91–93. 2013. View Article : Google Scholar
|
|
27
|
Nabhan C, Valley A and Feinberg BA:
Barriers to oncology biosimilars uptake in the United States.
Oncologist. 23:1261–1265. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Greenwald M, Tesser J and Sewell KL:
Biosimilars have arrived: Rituximab. Arthritis. 2018:37628642018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
European Generic medicines Association, .
The future of pharmaceuticals: Generic medicines enhancing
pharmaceutical competition and ensuring healthcare sustainability
issues. 2007, http://198.170.119.137/doc/ega_FuturePharmaceuticals.pdfJan
12–2019
|
|
30
|
US FDA, . FDA approves Truxima as
biosimilar to Rituxan for non-Hodgkin's lymphoma. 2018, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627035.htmJan
15–2019
|
|
31
|
Pimentel FF, Morgan G, Tiezzi DG and de
Andrade JM: Development of new formulations of Biologics:
Expectations, immunogenicity, and safety for subcutaneous
trastuzumab. Pharmaceut Med. 32:319–325. 2018.PubMed/NCBI
|
|
32
|
US FDA, . Drug Approval Package: Ontruzant
(trastuzumab-dttb). 2019, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761100Orig1s000TOC.cfmJan
18–2019
|
|
33
|
Uifălean A, Ilieş M, Nicoară R, Rus LM,
Hegheş SC and Iuga CA: Concepts and challenges of Biosimilars in
breast cancer: The emergence of trastuzumab biosimilars.
Pharmaceutics. 10:E1682018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
US FDA, . Drug Approval Package: OGIVRI
(trastuzumab-dkst). 2017, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761074Orig1s000TOC.cfmDec
1–2017
|
|
35
|
Rajasekaran N, Chester C, Yonezawa A, Zhao
X and Kohrt HE: Enhancement of antibody-dependent cell mediated
cytotoxicity: A new era in cancer treatment. Immunotargets Ther.
4:91–100. 2015.PubMed/NCBI
|
|
36
|
Syrigos KN: Bevacizumab in Lung Cancer:
Impact and Exceptional Cases. Focus on Health Ltd. Publications;
Athens: pp. 9–11. 2013
|
|
37
|
Grapsa D, Syrigos K and Saif MW:
Bevacizumab in combination with fluoropyrimidine-irinotecan- or
fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and
maintenance treatment of metastatic colorectal cancer. Expert Rev
Anticancer Ther. 15:1267–1281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Casak SJ, Lemery SJ, Chung J, Fuchs C,
Schrieber SJ, Chow ECY, Yuan W, Rodriguez L, Gwise T, Rowzee A, et
al: FDA's approval of the first biosimilar to bevacizumab. Clin
Cancer Res. 15:4365–4370. 2018. View Article : Google Scholar
|
|
39
|
Aapro M, Bokemeyer C, Ludwig H, Gascón P,
Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K and
Abraham I: Chemotherapy-induced (febrile) neutropenia prophylaxis
with biosimilar filgrastim in elderly versus non-elderly cancer
patients: Patterns, outcomes, and determinants (MONITOR-GCSF
study). J Geriatr Oncol. 8:86–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jelkmann W: Physiology and pharmacology of
erythropoietin. Transfus Med Hemother. 40:302–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tonelli M, Hemmelgarn B, Reiman T, Manns
B, Reaume MN, Lloyd A, Wiebe N and Klarenbach S: Benefits and harms
of erythropoiesis-stimulating agents for anemia related to cancer:
A meta-analysis. CMAJ. 180:E62–E71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xirou V, Gkiozos I, Grapsa D, Dimitroulis
I and Syrigos K: P2.01-039 Erythropoiesis-stimulating agents for
chemotherapy-induced anaemia in lung cancer: Efficacy, toxicity and
effect on survival. J Thorac Oncol. 12 (Suppl 2):S20842017.
View Article : Google Scholar
|
|
43
|
Irrera N, Bitto A, Pizzino G, Vaccaro M,
Squadrito F, Galeano M, Stagno d'Alcontres F, Stagno d'Alcontres F,
Buemi M, Minutoli L, et al: Epoetin alpha and Epoetin zeta: A
comparative study on stimulation of angiogenesis and wound repair
in an experimental model of burn injury. Biomed Res Int.
2015:9689272015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Smeeding J, Malone DC, Ramchandani M,
Stolshek B, Green L and Schneider P: Biosimilars: Considerations
for Payers. PT. 44:54–63. 2019.
|
|
45
|
Simoens S: Biosimilar medicines and
cost-effectiveness. Clinicoecon Outcomes Res. 3:29–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
European Generic medicines Association.
The future of pharmaceuticals, . Generic medicines enhancing
pharmaceutical competition and ensuring healthcare sustainability
issues. 2007. http://198.170.119.137/doc/ega_FuturePharmaceuticals.pdfFeb
1–2019
|
|
47
|
Abraham I, Han L, Sun D, MacDonald K and
Aapro M: Cost savings from anemia management with biosimilar
epoetin alfa and increased access to targeted antineoplastic
treatment: A simulation for the EU G5 countries. Future Oncol.
10:1599–1609. 2014. View Article : Google Scholar : PubMed/NCBI
|
